Cargando…
Glycemic Variation in Tumor Patients with Total Parenteral Nutrition
BACKGROUND: Hyperglycemia is associated with poor clinical outcomes and mortality in several patients. However, studies evaluating hyperglycemia variation in tumor patients receiving total parenteral nutrition (TPN) are scarce. The aim of this study was to assess the relationship between glycemia an...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717948/ https://www.ncbi.nlm.nih.gov/pubmed/26228214 http://dx.doi.org/10.4103/0366-6999.161358 |
_version_ | 1782410711236870144 |
---|---|
author | Yang, Jin-Cheng Dai, Yuan-Yuan Wang, Li-Ming Xie, Yi-Bin Zhou, Hai-Yan Li, Guo-Hui |
author_facet | Yang, Jin-Cheng Dai, Yuan-Yuan Wang, Li-Ming Xie, Yi-Bin Zhou, Hai-Yan Li, Guo-Hui |
author_sort | Yang, Jin-Cheng |
collection | PubMed |
description | BACKGROUND: Hyperglycemia is associated with poor clinical outcomes and mortality in several patients. However, studies evaluating hyperglycemia variation in tumor patients receiving total parenteral nutrition (TPN) are scarce. The aim of this study was to assess the relationship between glycemia and tumor kinds with TPN by monitoring glycemic variation in tumor patients. METHODS: This retrospective clinical trial selected 312 patients with various cancer types, whose unique nutrition treatment was TPN during the monitoring period. All patients had blood glucose (BG) values assessed at least six times daily during the TPN infusion. The glycemic variation before and after TPN was set as the indicator to evaluate the factors influencing BG. RESULTS: The clinical trial lasted 7.5 ± 3.0 days adjusted for age, gender, family cancer history and blood types. There were six cancer types: Hepatic carcinoma (HC, 21.8%), rectal carcinoma (17.3%), colon carcinoma (CC, 14.7%), gastric carcinoma (29.8%), pancreatic carcinoma (11.5%), and duodenal carcinoma (DC, 4.8%). The patients were divided into diabetes and nondiabetes groups. No statistical differences in TPN glucose content between diabetes and nondiabetes groups were found; however, the tumor types affected by BG values were obvious. With increasing BG values, DC, HC and CC were more represented than other tumor types in this sequence in diabetic individuals, as well as in the nondiabetic group. BG was inclined to be more easily influenced in the nondiabetes group. Other factors did not impact BG values, including gender, body mass index, and TPN infusion duration time. CONCLUSIONS: When tumor patients are treated with TPN, BG levels should be monitored according to different types of tumors, besides differentiating diabetes or nondiabetes patients. Special BG control is needed for DC, HC and CC in both diabetic and nondiabetic patients. If BG overtly increases, positive measurements are needed to control BG values. The ClinicalTrials.gov ID is NCT02024321. |
format | Online Article Text |
id | pubmed-4717948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-47179482016-04-04 Glycemic Variation in Tumor Patients with Total Parenteral Nutrition Yang, Jin-Cheng Dai, Yuan-Yuan Wang, Li-Ming Xie, Yi-Bin Zhou, Hai-Yan Li, Guo-Hui Chin Med J (Engl) Original Article BACKGROUND: Hyperglycemia is associated with poor clinical outcomes and mortality in several patients. However, studies evaluating hyperglycemia variation in tumor patients receiving total parenteral nutrition (TPN) are scarce. The aim of this study was to assess the relationship between glycemia and tumor kinds with TPN by monitoring glycemic variation in tumor patients. METHODS: This retrospective clinical trial selected 312 patients with various cancer types, whose unique nutrition treatment was TPN during the monitoring period. All patients had blood glucose (BG) values assessed at least six times daily during the TPN infusion. The glycemic variation before and after TPN was set as the indicator to evaluate the factors influencing BG. RESULTS: The clinical trial lasted 7.5 ± 3.0 days adjusted for age, gender, family cancer history and blood types. There were six cancer types: Hepatic carcinoma (HC, 21.8%), rectal carcinoma (17.3%), colon carcinoma (CC, 14.7%), gastric carcinoma (29.8%), pancreatic carcinoma (11.5%), and duodenal carcinoma (DC, 4.8%). The patients were divided into diabetes and nondiabetes groups. No statistical differences in TPN glucose content between diabetes and nondiabetes groups were found; however, the tumor types affected by BG values were obvious. With increasing BG values, DC, HC and CC were more represented than other tumor types in this sequence in diabetic individuals, as well as in the nondiabetic group. BG was inclined to be more easily influenced in the nondiabetes group. Other factors did not impact BG values, including gender, body mass index, and TPN infusion duration time. CONCLUSIONS: When tumor patients are treated with TPN, BG levels should be monitored according to different types of tumors, besides differentiating diabetes or nondiabetes patients. Special BG control is needed for DC, HC and CC in both diabetic and nondiabetic patients. If BG overtly increases, positive measurements are needed to control BG values. The ClinicalTrials.gov ID is NCT02024321. Medknow Publications & Media Pvt Ltd 2015-08-05 /pmc/articles/PMC4717948/ /pubmed/26228214 http://dx.doi.org/10.4103/0366-6999.161358 Text en Copyright: © 2015 Chinese Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Yang, Jin-Cheng Dai, Yuan-Yuan Wang, Li-Ming Xie, Yi-Bin Zhou, Hai-Yan Li, Guo-Hui Glycemic Variation in Tumor Patients with Total Parenteral Nutrition |
title | Glycemic Variation in Tumor Patients with Total Parenteral Nutrition |
title_full | Glycemic Variation in Tumor Patients with Total Parenteral Nutrition |
title_fullStr | Glycemic Variation in Tumor Patients with Total Parenteral Nutrition |
title_full_unstemmed | Glycemic Variation in Tumor Patients with Total Parenteral Nutrition |
title_short | Glycemic Variation in Tumor Patients with Total Parenteral Nutrition |
title_sort | glycemic variation in tumor patients with total parenteral nutrition |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717948/ https://www.ncbi.nlm.nih.gov/pubmed/26228214 http://dx.doi.org/10.4103/0366-6999.161358 |
work_keys_str_mv | AT yangjincheng glycemicvariationintumorpatientswithtotalparenteralnutrition AT daiyuanyuan glycemicvariationintumorpatientswithtotalparenteralnutrition AT wangliming glycemicvariationintumorpatientswithtotalparenteralnutrition AT xieyibin glycemicvariationintumorpatientswithtotalparenteralnutrition AT zhouhaiyan glycemicvariationintumorpatientswithtotalparenteralnutrition AT liguohui glycemicvariationintumorpatientswithtotalparenteralnutrition |